Company: CDT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024140
Chunk: 149

Company: CDT Equity Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 149
---
. The company has evolved into a broader, more agile platform that leverages
artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel therapeutic treatments.

CDT
Equity’s strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by
larger pharmaceutical companies with strong, supporting Phase I safety data. Through advanced co-crystallization and solid-form technologies
developed at our Cambridge facility, we aim to improve drug properties and have successfully extended patent life of certain drugs by
up to 20 years.

Our
current pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology
and animal health. The intellectual property portfolio comprises pending patent applications in several international jurisdictions describing
a solid-form compound, including the AZD1656 Cocrystal (a HK-4 Glucokinase Activator). Our pipeline research includes a number of compounds
that serve as promising alternatives to existing clinical assets currently marketed and sold by large pharmaceutical companies, which
we have identified as having an opportunity to develop further intellectual property positions through solid-form technology.

Our
collaboration with Sarborg enables us to apply proprietary algorithms utilizing AI-powered disease mapping to identify novel re-purposing
opportunities against a database of over 800 disease signatures. Sarborg’s insights have directly informed two new combination
patent filings, strengthening our intellectual property portfolio. In addition, Equity has initiated pre-clinical in-vitro models to
explore new indications, guided by AI-insights without human intervention. We will seek an exit through third-party license deals following
successful in vitro and in vivo pre-clinical trials, entering into agreements with third-parties to pursue further development, FDA approval,
commercialization and marketing of our assets . We continue to evaluate novel artificial intelligence and cybernetics approaches to drug
re-purposing, intellectual property and asset selection to give CDT a competitive advantage.

31

The Sarborg
Agreement, entered into between the Company and Sarborg on December 12, 2024 is designed to address longstanding challenges in the pharmaceutical
sector, in particular by reducing human error in critical decision-making processes in both clinical development and asset identification.
By integrating Sarborg’s algorithmic AI/cybernetics technology, CDT aims to enhance efficiency, lower costs, and accelerate timelines
by minimizing human intervention, ultimately optimizing the drug development cycle and giving CDT a competitive advantage in the